Edwards Lifesciences Corporation
EW
$76.04
$0.911.21%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 197.68% | 190.65% | 6.01% | -5.04% | -7.85% |
| Total Depreciation and Amortization | 7.11% | 3.97% | 6.76% | 5.78% | 3.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2,718.05% | -2,439.67% | 46.16% | -422.62% | -471.69% |
| Change in Net Operating Assets | 50.73% | 96.89% | -42.36% | -149.67% | -24.89% |
| Cash from Operations | -39.46% | -22.61% | -7.90% | -57.37% | -26.47% |
| Capital Expenditure | 0.24% | -24.53% | -23.55% | -10.03% | -3.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1,015.34% | -408.22% | 132.58% | 132.58% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -157.53% | -102.42% | 57.09% | 12.39% | 5.05% |
| Cash from Investing | 1,230.78% | 1,041.39% | 906.09% | 914.59% | -31.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.65% | 12.12% | 12.92% | 26.06% | 16.05% |
| Repurchase of Common Stock | -31.81% | -23.94% | 36.14% | 59.86% | 49.07% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -138.46% | 60.00% | 405.00% | 17.86% | 63.89% |
| Cash from Financing | -38.26% | -25.40% | 44.35% | 68.89% | 55.13% |
| Foreign Exchange rate Adjustments | 129.76% | -890.00% | 1,348.39% | 1,605.56% | -12.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 409.00% | 1,299.20% | 492.92% | 321.90% | 495.99% |